Bard Peripheral Vascular, Inc.

Bard Peripheral Vascular, Inc., a subsidiary of Becton, Dickinson and Company headquartered in Tempe, Arizona, supplies implantable vascular medical devices—stents, grafts, catheters, balloons, and related surgical implants—to the Department of Veterans Affairs and other federal healthcare agencies as a prime contractor competing without set-asides. The company operates almost entirely in the prime role (99% of recent awards) and has generated $67.5 million in combined potential value across 3,767 awards since 2005, with activity accelerating from 38 awards in 2022 to 73 in 2025.

Bard Peripheral Vascular's federal customer base concentrates heavily in the VA system. The five highest-volume VA VISNs account for 34 percent of all awards by count and 63 percent of combined potential value. Veterans Integrated Service Network 8 leads both rankings (382 awards, $11.7 million potential value), followed by VISN 10 (168 awards, $11.5 million) and VISN 22 (224 awards, $9 million). Beyond the VA, the company has placed orders with the Department of the Army Medical Command (46 awards, $3.3 million), the National Institutes of Health Clinical Center, and the Indian Health Service. Work is performed across multiple VA facilities and subordinate medical centers, with administrative oversight routed through the respective VISN contracting offices.

The capability portfolio centers on peripheral vascular surgical implants delivered through consignment-based procurement arrangements. Recent representative prime work includes a $4.7 million single-award indefinite delivery contract with VISN 10 (awarded November 2025) for peripheral vascular implants including drug-coated balloons, catheters, stents, and grafts; a $2.3 million IDC with VISN 22 (April 2024) for surgical implants extending through March 2028; a $359,640 blanket purchase agreement with VISN 17 (October 2025) for stent consignment; and individual purchase orders ranging from $5,000 to $90,000 across multiple VISNs for named products including LifeStent, Bard Fluency, Venovo, Covera, and Distaflo devices. Task orders under these vehicles are titled with product-specific descriptions: "vascular surgical stents," "prosthetics," "surgical implants," "stent grafts," and consignment restocking reports covering monthly or quarterly periods.

Bard Peripheral Vascular's vehicle position reflects a consignment-based contracting model typical of VA medical device procurement. The company holds multiple indefinite delivery contracts and blanket purchase agreements across VISNs, with the top five parent vehicles carrying 93 task orders and $1.8 million in combined potential value. These include IDC VA528P0192 (49 task orders, $431 thousand), BPA 36C24821A0031 (19 task orders, $693 thousand), and IDC SPE2DV17D1046 (10 task orders). The contracts are structured as firm-fixed-price consignment agreements, where Bard maintains on-site inventory at VA medical centers and invoices only when products are used. Most IDVs carry single-award, non-set-aside status and extend two to five years, reflecting the government's determination that Bard is either the sole manufacturer or the only source capable of meeting specifications at competitive pricing.

Activity has grown steadily. Awards increased from 38 in 2022 to 73 in 2025 (a near-doubling over four years), with 2026 showing six awards so far in a partial calendar year. Within the next twenty-four months, eight awards with combined potential value of $130 thousand face ultimate completion dates and therefore represent recompete exposure. The 2025 growth was driven by new or expanded IDC vehicles with VISN 10 and VISN 17 and continued consignment calls under existing BPAs, particularly with VISN 8.

Bard Peripheral Vascular subcontracts as a vendor to Cardinal Health 200, LLC across medical and surgical equipment supply orders dating from 2022 through December 2025. These sub-awards cover implantable ports, balloons, catheters, surgical implants, and mesh products, with Cardinal Health appearing to aggregate or redistribute Bard's products alongside other medical device manufacturers' offerings. Sub-award volume is minimal (39 of 3,767 total awards, or 1%) and concentrated within a single prime relationship.

NAICS coding reflects the device manufacturing and distribution scope. The top three NAICS codes are Surgical and Medical Instrument Manufacturing (1,163 awards), Surgical Appliance and Supplies Manufacturing (1,050 awards), and Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (371 awards). The primary PSC code is Medical and Surgical Instruments, Equipment, and Supplies (3,381 awards). All awards carry full-and-open (non-set-aside) designations, reflecting Bard Peripheral Vascular's competitive standing as an established OEM supplier to federal healthcare programs without reliance on small-business or socioeconomic preferences.

Bard Peripheral Vascular operates as the functional subsidiary within Becton, Dickinson and Company's vascular medical device portfolio, leveraging BD's parent-company certifications and contracting infrastructure. The consignment model and multi-VISN reach demonstrate a mature federal presence anchored to VA healthcare delivery and interventional vascular disease treatment for veteran populations.